Business
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead
About this update from Palvella Therapeutics, Inc.
[{"type":"text","content":"Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella’s Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company’s QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the appointment of Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. “As we prepare for a potential near-term U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, building strong market access and patient services capabilities is a key priority for Palvella,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Jennifer brings deep expertise in rare disease access strategy and patient support, as well as valuable rare skin disease experience from Krystal Biotech, where she contributed to the successful launch of VYJUVEK®, a first-in-disease topical therapy for dystrophic epidermolysis bullosa, a serious, rare genetic skin disease. We are excited to welcome her to the Palvella team as we work to support patients, caregivers, and providers from day one of our planned U.S. launch. We believe the exceptional talent we’re recruiting to Palvella provides a strong foundation for several new product launches as we advance our deep pipeline of therapies for serious, rare skin diseases and vascular malformations.” Ms. McDonough is an accomplished commercial leader with more than 25 years of experience supporting the launch and growth of rare disease and specialty therapies, including first-in-disease therapies for serious, rare skin diseases. She brings deep expertise in market access strategy, reimbursement, patient services, spe...